Clinical efficacy of collagenase <i>Clostridium histolyticum</i> in the treatment of Peyronie's disease by subgroup: results from two large, double‐blind, randomized, placebo‐controlled, phase <scp>III</scp> studies

Abstract

In this analysis, clinical efficacy of CCH treatment for reducing penile curvature deformity and PD symptom bother was found across subgroups. In the IMPRESS I and II overall, adverse events (AEs) were typically mild or moderate, although treatment-related serious AEs, including corporal rupture or penile haematoma, occurred. Future studies could be considered to directly assess the efficacy and safety of CCH treatment in defined subgroups of PD patients, with the goal of identifying predictors of optimum treatment success.